Akthelia Pharmaceuticals
Preclinical-stage biopharmaceutical company developing host-directed small-molecule therapeutics that boost innate immune function at epithelial surfaces. Primary programs target chemotherapy-induced mucosal barrier injury (to reduce febrile neutropenia and bloodstream infections) and wound healing; the company pursues translational preclinical development, IP generation, and collaborative R&D under European funding programs.
Industries
Nr. of Employees
small (1-50)
Akthelia Pharmaceuticals
Patents
Products
Oral prophylactic small-molecule candidate for chemotherapy-induced febrile neutropenia
Preclinical-stage oral small-molecule therapeutic designed to upregulate GI epithelial innate immunity to prevent microbiome translocation and reduce risk of febrile neutropenia and bloodstream infections in chemotherapy patients.
Topical small-molecule program for wound healing
Early-stage topical formulation program targeting wound healing (including diabetic wounds) by enhancing local epithelial immune resilience and promoting tissue regeneration.
Oral prophylactic small-molecule candidate for chemotherapy-induced febrile neutropenia
Preclinical-stage oral small-molecule therapeutic designed to upregulate GI epithelial innate immunity to prevent microbiome translocation and reduce risk of febrile neutropenia and bloodstream infections in chemotherapy patients.
Topical small-molecule program for wound healing
Early-stage topical formulation program targeting wound healing (including diabetic wounds) by enhancing local epithelial immune resilience and promoting tissue regeneration.
Services
Engages in multi-party research collaborations, consortium projects and exclusive licensing arrangements to develop and translate immune-modulating small molecules.
Engages in multi-party research collaborations, consortium projects and exclusive licensing arrangements to develop and translate immune-modulating small molecules.
Expertise Areas
- Host-directed immunotherapies for epithelial barriers
- Preclinical small-molecule drug discovery
- Mucosal/epithelial barrier biology and therapeutics
- CMC and formulation development (oral and topical)
Key Technologies
- High-throughput cell-based reporter screening
- Histone deacetylase (HDAC) modulation biology
- Host defense peptide induction assays
- Computer-aided drug design (in-silico)
News & Updates
Company presentation covering current status, next development steps and the path toward clinical trials; attended by shareholders, advisors and scientific network.
Presentation of translational mucosal barrier injury efficacy data and partnering objectives at a major life sciences conference.
Coverage of company activities and developments in Icelandic business newspaper.
Company employees are co-authors on a Drug Discovery Today paper exploring HDAC inhibitors' impact on macrophage polarization to enhance innate immunity against infections.
Joint award of a €6 million Horizon Europe grant to advance discovery and optimisation of innate immune system inducers addressing antimicrobial resistance.
Multiple RANNIS grants awarded to support wound healing development (2019) and regulatory/testing for the lead program (two-year $350,000 grant announced 2024).
Company presentation covering current status, next development steps and the path toward clinical trials; attended by shareholders, advisors and scientific network.
Presentation of translational mucosal barrier injury efficacy data and partnering objectives at a major life sciences conference.
Coverage of company activities and developments in Icelandic business newspaper.
Company employees are co-authors on a Drug Discovery Today paper exploring HDAC inhibitors' impact on macrophage polarization to enhance innate immunity against infections.
Joint award of a €6 million Horizon Europe grant to advance discovery and optimisation of innate immune system inducers addressing antimicrobial resistance.
Multiple RANNIS grants awarded to support wound healing development (2019) and regulatory/testing for the lead program (two-year $350,000 grant announced 2024).